Business Wire CORRECTING and REPLACING Law Firm Scott + Scott, LLC Announces Class Action Lawsuit Against Biovail Corporation issued Dec. 9, 2003.

Business Editors/Legal Writers

CORRECTION...by Business Wire

COLCHESTER, Conn.--(BUSINESS WIRE)--Dec. 10, 2003

In BW5195 issued Dec. 9, 2003: Headline of release dated Dec. 9, 2003 should read Law Firm Scott + Scott, LLC Announces Class Action Lawsuit Against Biovail Corporation sted Law Firm Scott + Scott, LLC Announces Class Action Lawsuit Against Biovail Shareholders

The rest of the release has not changed. It, with its adjusted headline (again) follow:

LAW FIRM SCOTT + SCOTT, LLC ANNOUNCES CLASS ACTION LAWSUIT AGAINST BIOVAIL CORPORATION

Scott + Scott, LLC Files Securities Action on Behalf of Biovail Shareholders; SEC Continues Inquiry Into Drugmaker's Accounting and Financial Reporting

Scott + Scott, LLC ([e-mail]), a law firm with offices in Connecticut and California, has filed a securities class action in the United States District Court for the Southern District of New York on behalf of all persons who purchased the common shares of Biovail Corporation (NYSE: BVF) (TSX: BVF) ("Biovail" or the "Company") between May 17, 2002 and October 30, 2003 (the "Class Period" or the "Class"). Following the action's filing, the Securities and Exchange Commission announced the commencement of an "informal inquiry" into the drugmaker's accounting and financial reporting. After the SEC's announcement, Biovail shares plummeted 20% to $18.51. Biovail shares opened trading today at $17.57.

The plaintiff-shareholder is pursuing remedies under the Securities Exchange Act of 1934 (the "Exchange Act"). A copy of the complaint filed in this action on behalf of investors is available from the Court or can be obtained by calling Scott + Scott, LLC at 800/404-7770, e-mailing the firm at [e-mail] or [e-mail], or by going to the firm's website (www.scott-scott.com) and clicking on "IN THE NEWS."

While Biovail has called this lawsuit "frivolous," the Canadian drugmaker has been criticized for not properly estimating inventories of its drugs; low revenue from its generic brand of Prilosec and excess inventory of heart drug Cardizem CD. Chief Executive Eugene Melnyk has been criticized for the purchase of a company plane by an entity he controlled, the use of Barbados as a tax shelter for Biovail, a doctor compensation program that pays doctors for using Cardizem LA and acquisitions that led to confusing accounting.

The Complaint alleges that Biovail and certain of its officers and directors made materially false and misleading statements during the Class Period. Specifically, Defendants made material misrepresentations concerning Biovail's financial results and business by improperly reporting revenue and earnings attributable to sales. Plaintiff further alleges that these material misrepresentations artificially inflated the price of Biovail's common shares, which traded as high as $ 50.30 on the New York Stock Exchange and as high as CD $ 67.75 on the Toronto Stock Exchange during the Class Period.

Scott + Scott, LLC is engaged in the representation of funds, foundations, endowments, institutions, pension funds, individuals, and other entities throughout the world in securities, antitrust and other complex class and non- class action litigation. The firm maintains the highest standards for client satisfaction and communication. The firm's attorneys litigate in both state and federal courts throughout the nation. The firm has been appointed lead counsel in cases nationwide, including the ongoing ImClone Securities Litigation. The firm also recently settled cases against Mattel and Emulex in which it was lead counsel. Scott + Scott, LLC issues this release in accordance with the applicable federal securities laws. If you wish to discuss this action, have any questions concerning this notice, your rights with respect to this matter or any other securities fraud matter please contact Neil Rothstein Esq.,[e-mail], or David Scott Esq., [e-mail], Scott + Scott, LLC, 108 Norwich Avenue, Colchester, Connecticut 06415 at 800/404-7770 (fax: [phone]).

Notice: This message is for addressee only and may contain privileged and/or confidential information. Any dissemination by anyone other than the intended recipient is strictly prohibited. If you have received this message in error, please delete it immediately.